TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
← catalyst calendarSponsored by Ascendis Pharma A/S (industry) · ASND — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
27actual
Sites
65
Countries
Georgia, Germany, Hungary +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The Sponsor made the decision to close enrollment as part of a strategic portfolio review.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-29 | actual | When the study began enrolling |
| Primary completion | 2025-03-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-28 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Head and Neck Neoplasms
Interventions
- Drug: TransCon TLR7/8 Agonist
- Drug: Pembrolizumab — also filed as Keytruda™
- Drug: TransCon IL-2 β/γ
Primary outcome
what the primary-completion date above is the date OFMajor Pathological Response
measured Up to 6 weeks after Cycle 2 (each cycle is 21 days)
Permalink · ASND's whole pipeline · Catalyst calendar · Every registered study · What changed